AbbVie ELAHERE OKd for Certain Ovarian Cancers

 The full approval of ELAHERE is based on the confirmatory MIRASOL Phase 3 trial that supports the medicine as a potential new standard of care for folate receptor alpha (FRα)-positive, platinum-resistant ovarian cancer (PROC)

-       Data show that ELAHERE treatment resulted in an overall survival benefit and reduced the risk of cancer progression by 35%
-       ELAHERE represents AbbVie's first approved solid tumor treatment following the recent acquisition of ImmunoGen

https://www.biospace.com/article/releases/u-s-food-and-drug-administration-fda-grants-full-approval-for-elahere-mirvetuximab-soravtansine-gynx-for-certain-ovarian-cancer-patients/